Advanced search
Publication Cover
Pediatric Hematology and Oncology Volume 32, 2015 - Issue 2
Submit an article Journal homepage
111
Views
8
CrossRef citations to date
0
Altmetric
Supportive Care

Natural History and Response to Treatment of HCV Infection Among Egyptian Survivors of Childhood Malignancy

Mona Saeed El-RazikyDepartment of Pediatrics, Cairo University, Cairo, Egypt
,
Eman Fawzy HalawaDepartment of Pediatrics, Cairo University, Cairo, Egypt
,
Iman Hassan DrazDepartment of Pediatrics, Cairo University, Cairo, EgyptCorrespondence[email protected]
&
Mona Samir AliDepartment of Pediatrics, National Hepatology and Tropical Medicine Institute, Cairo, Egypt
Pages 138-145 | Received 09 Jun 2014, Accepted 24 Aug 2014, Published online: 29 Sep 2014

REFERENCES

  • Kebudi R, Ayan I, Yílmaz G, et al. Seroprevalence of hepatitis B, hepatitis C and immunodeficiency virus infections in children with cancer at diagnosis and following therapy in Turkey. Med Pediatr Oncol. 2000;34:102–105.
  • Mostafa A, Ebeid E, Mansour T, et al. Seroprevalence of hepatitis B and C in pediatric malignancies. J Egyptian Nat. Cancer Inst. 2003;15:33–42.
  • Mohan N, Gonzalez- Peralta R, Fujisawa T, et al. Chronic hepatitis C virus infection in children. JPGN. 2010;50:123–131.
  • El-Sayed MH, Mohamed MM, Karim A, et al. Severe liver disease is caused by HBV rather than HCV in children with hematological malignancies. Hematol J. 2003;4(5):321–327.
  • Wirth S, Kelly D, Sokal E, et al. Guidance for clinical trials for children and adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2011;52(2):233–237.
  • Cesaro S, Bortolotti F, Petris MG, et al. An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy. Pediatr Blood Cancer. 2010;55:108–112.
  • Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431–435.
  • Cesaro S, Petris MG, Rossetti F, et al. Chronic hepatitis C virus infection after treatment for pediatric malignancy. Blood. 1997;90:1315–1320.
  • Sharaf- Eldeen S, Salama K, Eldemerdash S, Hassan HM. Hepatitis B and C viruses in Egyptian children with malignancy. J Med Sci. 2007;7:1003–1008.
  • Kose S, Olmezoglu A, Gozaydin A, Ece G. Seroprevalence of hepatitis B and C among oncology patients in Turkey. J Health Popul Nutr. 2011;29:652–655.
  • Strickland DK, Riely CA, Patrick CC, et al. Hepatitis C infection among survivors of childhood cancer. Blood. 2000;95:3065–3070.
  • Castellino S, Lensing S, Riely C, et al. The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude children's research hospital hepatitis C seropositive cohort. Blood. 2004;103:2460–2466.
  • El-Raziky MS, El-Hawary M, El-Koofy N, et al. Hepatitis C virus infection in Egyptian children: single centre experience. J Viral Hepat. 2004;11:471–476.
  • Paul IM, Sanders J, Ruggiero F, et al. Chronic hepatitis C virus infections in leukemia survivors: prevalence, viral load, and severity of liver disease. Blood. 1999;93:3672–3677.
  • Locasciulli A, Testa M, Pontisso P, et al. Prevalence and natural history of hepatitis C infection in patients cured of childhood Leukemia. Blood. 1997;90:4628–4633.
  • Esmat G, Hashem M, El-Raziky M, et al. Risk factors for hepatitis C virus acquisition and predictors of persistence among Egyptian children. Liver Int. 2012;32:449–456.
  • Locasciulli A, Cavalletto D, Pontisso P, et al. Hepatitis C virus serum markers and liver disease in children with leukemia during and after chemotherapy. Blood. 1993;82:2564–2567.
  • Fioredda F, Moser A, Bertoluzzo L, et al. Natural course of HCV infection in childhood cancer survivors. Support Care Cancer. 2010;18:1413–1420.
  • Lo Nigro L, la spina M, Mirabile E, et al. Use of peg-interferon alfa 2-a plus ribavirin as treatment for chronic HCV hepatitis in a child cured of ALL. Pediatr Blood Cancer. 2004;4:185.
  • Ghaffar TY, El Naghy S, El Sebaie H, et al. Pegylated α interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection. Indian J Pediatr. 2009;76:895–898.
  • El Naghi S, Abdel-Ghaffar TY, El-Karaksy H, et al. Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children. World J Gastroenterol. 2014;20(16):4681–4691.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.